398 related articles for article (PubMed ID: 19493313)
1. The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma.
Madhunapantula SV; Robertson GP
Pigment Cell Melanoma Res; 2009 Aug; 22(4):400-19. PubMed ID: 19493313
[TBL] [Abstract][Full Text] [Related]
2. Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma.
Marsh Durban V; Deuker MM; Bosenberg MW; Phillips W; McMahon M
J Clin Invest; 2013 Dec; 123(12):5104-18. PubMed ID: 24200692
[TBL] [Abstract][Full Text] [Related]
3. In vitro treatment of melanoma brain metastasis by simultaneously targeting the MAPK and PI3K signaling pathways.
Daphu I; Horn S; Stieber D; Varughese JK; Spriet E; Dale HA; Skaftnesmo KO; Bjerkvig R; Thorsen F
Int J Mol Sci; 2014 May; 15(5):8773-94. PubMed ID: 24840574
[TBL] [Abstract][Full Text] [Related]
4. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
5. Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development.
Cheung M; Sharma A; Madhunapantula SV; Robertson GP
Cancer Res; 2008 May; 68(9):3429-39. PubMed ID: 18451171
[TBL] [Abstract][Full Text] [Related]
6. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA
Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840
[TBL] [Abstract][Full Text] [Related]
7. Functional and therapeutic significance of Akt deregulation in malignant melanoma.
Robertson GP
Cancer Metastasis Rev; 2005 Jun; 24(2):273-85. PubMed ID: 15986137
[TBL] [Abstract][Full Text] [Related]
8. A minireview: the role of MAPK/ERK and PI3K/Akt pathways in thyroid follicular cell-derived neoplasm.
Brzezianska E; Pastuszak-Lewandoska D
Front Biosci (Landmark Ed); 2011 Jan; 16(2):422-39. PubMed ID: 21196179
[TBL] [Abstract][Full Text] [Related]
9. Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor.
Bonnevaux H; Lemaitre O; Vincent L; Levit MN; Windenberger F; Halley F; Delorme C; Lengauer C; Garcia-Echeverria C; Virone-Oddos A
Mol Cancer Ther; 2016 Jul; 15(7):1460-71. PubMed ID: 27196754
[TBL] [Abstract][Full Text] [Related]
10. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells.
Gopal YN; Deng W; Woodman SE; Komurov K; Ram P; Smith PD; Davies MA
Cancer Res; 2010 Nov; 70(21):8736-47. PubMed ID: 20959481
[TBL] [Abstract][Full Text] [Related]
11. Ferulic Acid Exerts Anti-Angiogenic and Anti-Tumor Activity by Targeting Fibroblast Growth Factor Receptor 1-Mediated Angiogenesis.
Yang GW; Jiang JS; Lu WQ
Int J Mol Sci; 2015 Oct; 16(10):24011-31. PubMed ID: 26473837
[TBL] [Abstract][Full Text] [Related]
12. [Dermatological implications of the PI3K pathway].
Dereure O
Ann Dermatol Venereol; 2015 Oct; 142(10):622-3. PubMed ID: 26001484
[No Abstract] [Full Text] [Related]
13. Timp1 interacts with beta-1 integrin and CD63 along melanoma genesis and confers anoikis resistance by activating PI3-K signaling pathway independently of Akt phosphorylation.
Toricelli M; Melo FH; Peres GB; Silva DC; Jasiulionis MG
Mol Cancer; 2013 Mar; 12():22. PubMed ID: 23522389
[TBL] [Abstract][Full Text] [Related]
14. BRAFV600E cooperates with PI3K signaling, independent of AKT, to regulate melanoma cell proliferation.
Silva JM; Bulman C; McMahon M
Mol Cancer Res; 2014 Mar; 12(3):447-63. PubMed ID: 24425783
[TBL] [Abstract][Full Text] [Related]
15. Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition.
Shi H; Kong X; Ribas A; Lo RS
Cancer Res; 2011 Aug; 71(15):5067-74. PubMed ID: 21803746
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of phosphatidylinositol-3-kinase and mitogen-activated protein kinase kinase 1/2 prevents melanoma development and promotes melanoma regression in the transgenic TPRas mouse model.
Bedogni B; Welford SM; Kwan AC; Ranger-Moore J; Saboda K; Powell MB
Mol Cancer Ther; 2006 Dec; 5(12):3071-7. PubMed ID: 17172409
[TBL] [Abstract][Full Text] [Related]
17. Targeting protein kinase-b3 (akt3) signaling in melanoma.
Madhunapantula SV; Robertson GP
Expert Opin Ther Targets; 2017 Mar; 21(3):273-290. PubMed ID: 28064546
[TBL] [Abstract][Full Text] [Related]
18. PRAS40 deregulates apoptosis in malignant melanoma.
Madhunapantula SV; Sharma A; Robertson GP
Cancer Res; 2007 Apr; 67(8):3626-36. PubMed ID: 17440074
[TBL] [Abstract][Full Text] [Related]
19. Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade.
Ogawa K; Sun C; Horii A
Oncol Rep; 2005 Dec; 14(6):1481-5. PubMed ID: 16273242
[TBL] [Abstract][Full Text] [Related]
20. Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma.
Kwong LN; Davies MA
Clin Cancer Res; 2013 Oct; 19(19):5310-9. PubMed ID: 24089444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
